RxDoctor Payments Data

Deanna Schrotberger, APRN

Psychiatric/Mental Health · Bridgeport, NENPI 1679045108

Payments from drug & device makers

$2,043in general payments, 2019–2025

Across 110 payments — averaging $18.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$672
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$434
  • Otsuka America Pharmaceutical, Inc.$331
  • Johnson & Johnson$232
  • Alkermes, Inc.$158
  • Axsome Therapeutics, Inc.$55
  • plus $161 from 5 others

What the payments were for

  • Food & beverage$1,99197%
  • Education$523%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,043 in reported general payments places this provider in the 65th percentile of 255 psychiatric/mental health providers in Nebraska.

See all psychiatric/mental health providers in Nebraska

Medicare billing

Part B allowed, 2024
$27,854
Medicare patients
19
Services billed
87

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl40$93,312
Invega SustennaPaliperidone Palmitate11$35,170
VraylarCariprazine Hcl20$28,095
RexultiBrexpiprazole16$23,119
TrintellixVortioxetine Hydrobromide21$10,228
VyvanseLisdexamfetamine Dimesylate19$7,676
Lisdexamfetamine Dimesylate24$6,796
Fluphenazine Hcl12$5,770
MovantikNaloxegol Oxalate11$4,464
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine53$2,567
Ziprasidone Hcl32$2,151
Quetiapine Fumarate174$2,129
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine93$1,632
Desvenlafaxine Succinate ErDesvenlafaxine Succinate16$1,538
Duloxetine Hcl52$1,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato, Invega Sustenna$232$128,48251 claims
AbbVieVraylar$672$28,09520 claims
Otsuka America Pharmaceutical, Inc.Rexulti$331$23,11916 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$16$17,90340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 255 psychiatric/mental health providers in Nebraska.

Other psychiatric/mental health in Bridgeport

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →